Stevens-Johnson syndrome induced by the cross-reactivity between teicoplanin and vancomycin.
OBJECTIVE
The glycopeptide antibiotics, vancomycin and teicoplanin, are the mainstay of therapy for severe gram-positive organisms such as methicillin-resistant Staphylococcus aureus. We report a case of Stevens-Johnson syndrome (SJS) induced by sequential therapy with teicoplanin and vancomycin, in a patient with chronic obstructive pulmonary disease (COPD).


METHODS
A 74-year-old Han Chinese with 1-year history of COPD was admitted for treatment of infective endocarditis. After teicoplanin therapy for 12 days, he developed pruritus and maculopapular over his trunk and limbs. His rash spread rapidly to most parts of the body surface area, 7 days after his anti-infection therapy was switched to vancomycin. This was stopped, but he developed SJS when teicoplanin was re-introduced. This patient recovered from his drug eruptions when both teicoplanin and vancomycin were stopped. Pharmacogenetic analyses revealed he was heterozygous with respect to two variants (rs2844682 of MUC21 and rs750332 of BAG6).


CONCLUSIONS
Cross-reactivity between vancomycin and teicoplanin is rare. SJS attributable to sequential treatment with these two antibiotics has not been reported previously. Care should be taken when prescribing vancomycin in patients with a previous documented skin eruption to teicoplanin, especially in those who carry any susceptibility alleles to SJS/TEN.
Department of Pharmacy, Beijing Hospital, Ministry of Health, Beijing, China.
L-P
LP
Yang
A-L
AL
Zhang
D-D
DD
Wang
H-X
HX
Ke
Q
Q
Cheng
C
C
Wang
D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects*; D044466:Asian People; D003429:Cross Reactions; D006801:Humans; D008297:Male; D008562:Membrane Glycoproteins / Q000235:genetics; D018832:Molecular Chaperones / Q000235:genetics; D009077:Mucins / Q000235:genetics; D010597:Pharmacogenetics; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy; D013262:Stevens-Johnson Syndrome / Q000209:etiology* / Q000503:physiopathology; D017334:Teicoplanin / Q000008:administration & dosage / Q000009:adverse effects*; D014640:Vancomycin / Q000008:administration & dosage / Q000009:adverse effects*
D000900:Anti-Bacterial Agents; C092009:BAG6 protein, human; C527666:MUC21 protein, human; D008562:Membrane Glycoproteins; D018832:Molecular Chaperones; D009077:Mucins; D017334:Teicoplanin; D014640:Vancomycin
Stevens-Johnson syndrome; teicoplanin; vancomycin